Wang Ying-Juan, Pan Kai-Li, Zhao Xiao-Li, Qiang Huan, Cheng Sheng-Quan
Department of Pediatrics, First Yulin Hospital,Yulin, Shaanxi, China.
Zhongguo Dang Dai Er Ke Za Zhi. 2011 Nov;13(11):855-8.
To study the efficacy of erythropoietinin (EPO) in the treatment of moderate or severe hypoxic-ischemic encephalopathy (HIE) in neonates.
Seventy neonates with moderate or severe HIE were randomly assigned to two groups: EPO treatment and control (n=35 each). The EPO treatment group included 22 cases of moderate HIE and 13 cases of severe HIE. The control group included 24 cases of moderate HIE and 11 cases of severe HIE. Thirty-five healthy full-term infants served as normal group. The control group received a conventional treatment. Beside the conventional treatment, the EPO treatment group was intravenously injected with EPO of 200 IU/kg•d, 3 times weekly. Routine blood test was performed every 6 days. EPO dose was adjusted based on the results of the routine blood test. The course of EPO treatment was 2 to 4 weeks. Neonatal Behavioral Neurological Assessment (NBNA) was performed at age of 28 days. The infant development test of Child Development Centre of China (CDCC) was performed at ages of 3 months and 6 months.
The percentage of normal NBNA scores in the EPO treatment group was significantly higher than that in the control group at age of 28 days (P<0.05), but was significantly lower than that in the normal group (P<0.01). The CDCC test including physical development index (PDI) and physical development index (MDI) showed the percentage of normal results in the EPO treatment group was significantly higher than in the control group at age of 3 months (P<0.05), but was significantly lower than in the normal group (P<0.01). The CDCC test including PDI and MDI showed that the percentage of normal results in the EPO treatment group was significantly higher than in the control group at age of 6 months. The MDI test results in the EPO treatment group were not significantly different from those in the normal group at age of 6 months, but the percentage of normal results in the PDI test in the EPO treatment group was still significantly lower than that in the normal group (P<0.05).
EPO treatment has neuroprotective effects against moderate or severe HIE and improves long-term behavioral neurological developments in neonates.
研究促红细胞生成素（EPO）治疗新生儿中重度缺氧缺血性脑病（HIE）的疗效。
将70例中重度HIE新生儿随机分为两组：EPO治疗组和对照组（每组n = 35）。EPO治疗组中，中度HIE 22例，重度HIE 13例。对照组中，中度HIE 24例，重度HIE 11例。35例健康足月儿作为正常组。对照组接受常规治疗。EPO治疗组在常规治疗基础上，静脉注射EPO 200 IU/kg•d，每周3次。每6天进行一次血常规检查，并根据血常规结果调整EPO剂量。EPO治疗疗程为2至4周。在出生28天时进行新生儿行为神经评定（NBNA）。在3个月和6个月时进行中国儿童发展中心（CDCC）婴儿发育测试。
EPO治疗组在出生28天时NBNA评分正常的百分比显著高于对照组（P<0.05），但显著低于正常组（P<0.01）。包括体格发育指数（PDI）和智力发育指数（MDI）的CDCC测试显示，EPO治疗组在3个月时测试结果正常的百分比显著高于对照组（P<0.05），但显著低于正常组（P<0.01）。包括PDI和MDI的CDCC测试显示，EPO治疗组在6个月时测试结果正常的百分比显著高于对照组。EPO治疗组在6个月时MDI测试结果与正常组无显著差异，但EPO治疗组PDI测试结果正常的百分比仍显著低于正常组（P<0.05）。
EPO治疗对新生儿中重度HIE具有神经保护作用，并改善其长期行为神经发育。
